TEVA R&D Increase and Bristol Recruit Emphasize Biosimilars
This article was originally published in RPM Report
Executive Summary
The Obama Administration failed to clarify the biosimlar pathway for the start of 2012 with promised guidances, but the big players in biosimilars think they have a good fix on what the space will look like from a regulatory/development perspective. Take TEVA; the generic company’s actions and statements at the end of 2011 announce clearly that it sees a development-intensive, beyond-generic space developing in biosimilars.